INTerpath-014NCT07513376
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 26 versions: 25 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 124 → 129 locations
- Minor Study sites: 124 to 126
- Minor Trial sites expanded: 117 → 124 locations
- Minor Study sites: 117 to 119
- Minor Trial sites expanded: 104 → 117 locations
- Minor Trial sites expanded: 94 → 104 locations
- Minor Study sites: 93 to 94
- Notable Eligibility criteria expanded, about 16 words
- Trial sites expanded: 86 → 93 locations
- Secondary endpoints: details revised at 6 of 8 entries
- Minor Trial sites expanded: 76 → 86 locationsv18
- Minor Trial sites expanded: 68 → 76 locationsv17
- Minor Trial sites expanded: 60 → 68 locationsv16
- Minor Trial sites expanded: 56 → 60 locationsv15
- Minor Trial sites expanded: 46 → 56 locationsv13
- Minor Trial sites expanded: 42 → 46 locationsv12
- Minor Trial sites expanded: 35 → 42 locationsv11
- Minor Trial sites expanded: 29 → 35 locationsv10
- Minor Trial sites expanded: 17 → 29 locationsv9
- Minor Trial sites expanded: 10 → 17 locationsv8
- Minor Study sites: 8 to 10v7
- Minor Study sites: 7 to 8v6
- Minor Study sites: 6 to 7v5
- Minor Study sites: 5 to 6v4
- Notable Recruitment opened
- Trial sites expanded: 0 → 3 locations
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 3
- Start date changed from estimate of May 11, 2026 to May 4, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (8)
Show 3 moreShow less
Arms and interventions
Participants will receive intismeran 1 mg via intramuscular (IM) injection plus pembrolizumab coformulated with berahyaluronidase alfa 790 mg via subcutaneous (SC) injection.
Participants will receive intismeran 1 mg via IM injection.
Participants will receive dose-matched placebo via IM injection.
Biologicals: Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa
Other: Placebo
Sites
129 sites in 20 countries
United States 28, Spain 9, Netherlands 8, Turkey (Türkiye) 8, Hungary 7, South Korea 7, Chile 6, Colombia 6, Israel 6, Italy 6, Taiwan 5, Canada 4, Germany 4, Greece 4, Japan 4, Poland 4, United Kingdom 4, Australia 3, Brazil 3, France 3